Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6598MR)

This product GTTS-WQ6598MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6598MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7177MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ5969MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ15509MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ2900MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ626MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ7216MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ1243MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ4002MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW